Multicenter study of Matrix Metalloproteinase (MMP)-9 expression on meibomian gland dysfunction using dry eye diagnostic device "InflammaDry"

Multicenter study of Matrix Metalloproteinase (MMP)-9 expression on meibomian gland dysfunction using dry eye diagnostic device "InflammaDry" - MMP-9 expression on meibomian gland dysfunction using dry eye diagnostic device InflammaDry

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017117

Enrollment

100

Registered

2015-04-15

Start date

2015-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction

Interventions

Gently dab the sampling fleece in multiple locations along the lower palpebral conjunctiva. Place the sampling fleece of the sample collector into test cassette and open the buffer vial and immerse t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as MGD Outpatients

Exclusion criteria

Exclusion criteria: Patients who may have the possibility of contagious diseases

Design outcomes

Primary

Measure	Time frame
MMP-9 positive expression on InflammaDry in patients with meibomian gland dysfunction	—

Secondary

Measure	Time frame
Slit-lamp findings, meibo-score, Schirmer test, tear break-up time	—

Countries

Japan

Contacts

Public ContactTohru Sakimoto

Nihon University School of Medicine Ophthalmology

torusaki@gmail.com03-3972-8111(2531)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Multicenter study of Matrix Metalloproteinase (MMP)-9 expression on meibomian gland dysfunction using dry eye diagnostic device &quot;InflammaDry&quot;